NASDAQ

Novartis’ Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...

Novartis’ Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...

Novartis’ Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...

Novartis’ Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...

Dynavax to Present at the Cowen & Co. Annual Health Care Conference

BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today ...

Dynavax to Present at the Cowen & Co. Annual Health Care Conference

BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today ...

G1 Therapeutics Announces Proposed Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), ...

G1 Therapeutics Announces Proposed Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), ...